Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Continued Genzyme Problems Offer Gaucher Opportunity To Competitors

Executive Summary

Genzyme's Allston Landing, Mass., plant - currently the only facility that produces its Cerezyme and Fabrazyme drugs - resumed working at full capacity on Aug. 28. But it seems the big biotech's manu-facturing woes are far from over: a mid-August visit by the European Medicines Agency found deficiencies, and a critical FDA inspection is still to come
Advertisement

Related Content

FDA Awaits Data On Clinical Significance Of Vimizim Neutralizing Antibodies
Genzyme Says Cerezyme Sales Fell 70%, But Allston Plant Production Is On Track
Genzyme Is Ready For FDA: Geoff McDonough Explains What The Firm Is Doing To Overcome Its Problems
Osiris Will Focus On Liver GvHD While Sorting Data From Failed Studies
FDA To Follow EMEA's Lead: ODAC Votes To Require Randomized Controlled Trials For Future Cutaneous T-Cell Lymphoma Drug Approval
Shire Files NDA For Gaucher Disease Drug With Data Showing Non-Inferiority To Cerezyme
EMEA Inspection Findings Portend Further Manufacturing Problems For Genzyme
Protalix Drug Set To Compete In Tough Gaucher Market Via Early Access Scheme
Multiple Factors Suggest Genzyme Still Faces Problems Related To Cerezyme
Genzyme Says Work At Allston Plant Will Resume As Planned Later This Month

Topics

Advertisement
UsernamePublicRestriction

Register

PS051447

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel